EMEA-002597-PIP01-19-M02 - paediatric investigation plan
Efgartigimod alfa
PIPHuman
Key facts
- Invented name
- Vyvgart
- Active Substance
- Efgartigimod alfa
- Therapeutic area
- Nervous system disorders
- Decision number
- P/0298/2024
- PIP number
- EMEA-002597-PIP01-19-M02
- Pharmaceutical form(s)
- Concentrate for solution for infusion
- Condition(s) / indication(s)
- Treatment of myasthenia gravis
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Argenx
E-mail: regulatory@argenx.com
Tel. +32 93103400- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date